Glenmark has announced the approval in 13 European countries of its Ryaltris (olopatadine hydrochloride / mometasone furoate) 665mcg/25mcg nasal spray. The Indian company and marketing partner Menarini are set to begin rolling out the treatment for seasonal and perennial allergic rhinitis in adults and children over 12, following earlier launches in certain other international territories.
Earlier this year, Glenmark revealed that it had concluded its decentralized European marketing authorization application procedure, “paving the way for...








